{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-023715","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.041320+00:00","generated_at":"2026-05-17T13:42:41.219206+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Abeona reports Q2 net income of $108.8M on PRV sale; ZEVASKYN launch on track","bullets":["Net income $108.8M ($2.07 basic EPS) vs $7.4M in Q2 2024; includes $155M gain from PRV sale.","Cash $225.9M expected to fund operations over two years without anticipated ZEVASKYN revenue.","First ZEVASKYN patient treatment expected in Q3 2025; multiple patients identified at QTCs.","100% of prior authorization requests approved; United Healthcare issued favorable coverage policy.","R&D expense fell to $5.9M; SG&A rose to $17.1M due to commercial launch costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-023715","json":"https://secwatch.observer/filing/0001641172-25-023715.json","markdown":"https://secwatch.observer/filing/0001641172-25-023715.md","text":"https://secwatch.observer/filing/0001641172-25-023715.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000164117225023715/0001641172-25-023715-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000164117225023715/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:42:41.219206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}